14 August 2014
A study, published in the online edition of the journal Cancer Research, has found why a certain cancer treatment may be ineffective with some patients.
Retinoic acid - a form of vitamin A - is used in cancer treatment to reduce the chance of recurrence of the disease, but some patients have been unresponsive. A team of researchers from Virginia Commonwealth University Massey Cancer Center have now found out that this is because of the presence of a protein.
The team, led by Professor Devanand Sarkar, demonstrated that a protein known as AEG-1 blocks the benefits of retinoic acid in leukemia and liver cancer and, as AEG-1 is overexpressed in most cancers, these findings could significantly impact cancer treatment.
They found that AEG-1 binds to retinoid X receptors, which help regulate cell growth and development and is typically activated by retinoic acid. However, the high levels of AEG-1 proteins found in cancer cells block these signals and help promote tumour growth.
Professor Sarkar said: "This research has immediate clinical relevance such that physicians could begin screening cancer patients for AEG-1 expression levels in order to determine whether retinoic acid should be prescribed."
Posted by Philip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.